Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) Gains from Investment Securities (2016 - 2017)

Tenax Therapeutics' Gains from Investment Securities history spans 5 years, with the latest figure at $3.8 million for Q3 2017.

  • For Q3 2017, Gains from Investment Securities rose 6218.58% year-over-year to $3.8 million; the TTM value through Sep 2017 reached $3.8 million, up 6218.58%, while the annual FY2023 figure was -$1125.0, 138.78% down from the prior year.
  • Gains from Investment Securities for Q3 2017 was $3.8 million at Tenax Therapeutics, up from $701610.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $4.7 million in Q1 2017 and bottomed at -$3626.0 in Q3 2014.
  • The 5-year median for Gains from Investment Securities is $60000.0 (2016), against an average of $1.2 million.
  • The largest annual shift saw Gains from Investment Securities crashed 109.12% in 2014 before it skyrocketed 104083.62% in 2015.
  • A 5-year view of Gains from Investment Securities shows it stood at $550.0 in 2013, then soared by 559.27% to $3626.0 in 2014, then crashed by 65.53% to $1250.0 in 2015, then soared by 5851.04% to $74388.0 in 2016, then surged by 4996.45% to $3.8 million in 2017.
  • Per Business Quant, the three most recent readings for TENX's Gains from Investment Securities are $3.8 million (Q3 2017), $701610.0 (Q2 2017), and $4.7 million (Q1 2017).